2. Menopause

3. Health screening of healthy postmenopausal women

4. The impact of postmenopausal estrogen deprivation

5. Menopausal hormone therapy and the risk of breast cancer

6. Menopausal hormone therapy and the risk of cardiovascular

7. Preparation for menopausal hormone therapy

8. Choice of estrogen/progestin regimen

9. Other symptoms that respond to estrogen therapy

10. Use of Contraceptives during the menopausal transition

11. Stopping hormone therapy and tapering

12. Compounded bio-identical hormone therapy

13. Exercise role in prevention and treatment osteoporosis

14. Calcium/vitamin D supplementation in osteoporosis

15. Intensity of exercise

16. Fracture risk assessment

17. Candidates for treatment of osteoporosis and osteopenia in postmenopausal women

18. The use of bisphosphonates in postmenopausal women with osteoporosis

19. Contraindications/intolerance of bisphosphonates

20. Pretreatment evaluation of bisphosphonates therapy

21. Risk of bisphosphonate therapy in patient with osteoporosis

22. Combination therapy

23. When to initiate bisphosphonates

24. Fracture healing in patients already taking bisphosphonates

25. Guidelines for monitoring response to therapy

26. Bone mineral density stable or increased

27. Bone mineral density decreased or fracture during therapy

28. Parathyroid hormone/parathyroid hormone-related protein analog

29. Denosumab for osteoporosis

30. Selective estrogen receptor modulators (Raloxifene)

31. Calcitonin for osteoporosis

32. Isoflavones supplements

33. Risk factors of menopausal hotflashes

34. Duration of menopausal hotflashes

35. Clinical manifestations of menopausal hotflashes

36. Differential diagnosis of hotflashes

37. Menopausal hormone therapy in women with menopausal hotflashes

38. Bazedoxifene/conjugated estrogen for treatment of menopausal hotflashes

39. SSRIs/SNRIs for treatment of menopausal hotflashes

40. Gabapentin for treatment of menopausal hotflashes

41. Paroxetine for treatment of menopausal hotflashes

42. Clonidine for treatment of menopausal hotflashes

43. Depot medroxiprogesteron acetate for treatment of menopausal hotflashes

44. hotflashes in women with breast cancer

45. Plant based therapy for treatment of menopausal hotflashes

46. Acupuncture for treatment of menopausal hotflashes

47. Clonidine for treatment of menopausal hotflashes

48. Autoimmune endocrinopathies in women with premature menopause

49. Spontaneous ovulation in women with premature menopause

50. Role of estrogen, clomiphene, gonadotropin, glucocorticoid therapy in infertile women with POF

51. Approach to Management of women with POF

52. Contraception in women with premature menopause

53. Duration of therapy in women with premature menopause

54. Androgen replacement therapy in women with premature menopause

55. Etiology postmenopausal uterine bleeding

56. Risk factors endometrial cancer

57. Endometrial evaluation
Endometrial biopsy
Dilation and curettage
Hysteroscopy
Saline infusion sonohysterography
Transvaginal ultrasound

58. Asymptomatic menopausal women with endometrial thickening

59. Asymptomatic menopausal women with fluid within the endometrial cavity

60. Endometrial thickening in women on hormone therapy

61. Endometrial thickening in women on tamoxifen

62. An ultrasound risk-scoring model for prediction of endometrial cancer in post-menopausal women

63. Endometrial hyperplasis: terminology and histologic class (2015, WHO)

64. Classification system Histologic category
2015 WHO
Normal endometrium
Hyperplasia without atypia (non-neoplastic)
Atypical hyperplasia (neoplastic)
Endometrial carcinoma
1994 WHO
Simple hyperplasia without atypia
Complex hyperplasia without atypia
Simple Atypical hyperplasia (rare)
Complex Atypical hyperplasia
Endometrial intraepithelial neoplasia
Benign endometrial hyperplasia
Additional terms used in
Proliferative endometrium
Disordered proliferative endometrium
Gland crowding

65. Management of proliferative endometrium

66. Management of nonatypical hyperplasia/benign endometrial hyperplasia (and some EIN)

67. Complex hyperplasia without atypia benign endometrial hyperplasia (some EIN)/gland crowding

68. Atypical hyperplasia/EIN

69. The end